Time and again, the scientists, doctors, drug makers and regulators who gathered Tuesday in Kansas City to talk about new cancer drugs spoke of the "valley of death." It's the long-cursed chasm between jaw-dropping breakthroughs in basic science — often unearthed at universities — and the manufacture of drugs that can battle your tumor.
New drugs are being approved at about the same rate they were in 1950, a rate the assembled experts said belied advances in medical research.
Tuesday's symposium was convened in response to large pharmaceutical companies moving away from start-to-finish drug development. Instead — and with unimpressive success — they have experimented with partnerships with academics and clinicians.
Since September, 16 major drug companies have inked deals with the Trump administration to lower prices....
